Peter Loh

Dr. Peter Loh

Department of Cardiology, University Medical Centre Utrecht, Utrecht, The Netherlands

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2020 in Circulation: Arrhythmia and Electrophysiology
Verified
Journal Article
Closed access
PDF file
Peter LohPeter Loh
Peter Loh
RERené van Es
René van Es
MGMarijn H.A. Groen
Marijn H.A. Groen
KNKars Neven
Kars Neven
WKWil Kassenberg
Wil Kassenberg
PDP. A. Doevendans
P. A. Doevendans
Background - Irreversible electroporation (IRE) is a promising new non-thermal ablation technology for pulmonary vein (PV) isolation in patients with atrial fibrillation (AF). Experimental data suggest that IRE ablation produces large enough lesions without the risk of PV stenosis, artery, nerve or esophageal damage. This study aimed to investigate the feasibility and safety of single pulse IRE PV isolation in patients with AF. Methods - Ten patients with symptomatic paroxysmal or persistent AF underwent single pulse IRE PV isolation under general anesthesia. Three-dimensional reconstruction and electroanatomical voltage mapping (EnSite PrecisionTM, Abbott) of left atrium and PVs were performed using a conventional circular mapping catheter. PV isolation was performed by delivering non-arcing, non-barotraumatic 6 ms, 200 J direct current IRE applications via a custom non-deflectable 14-polar circular IRE ablation catheter with a variable hoop diameter (16-27 mm). A deflectable sheath (AgilisTM, Abbott) was used to maneuver the ablation catheter. A minimum of two IRE applications with slightly different catheter positions were delivered per vein to achieve circular tissue contact, even if PV potentials were abolished after the first application. Bidirectional PV isolation was confirmed with the circular mapping catheter and a post ablation voltage map. After a 30-minute waiting period, adenosine testing (30 mg) was used to reveal dormant PV conduction. Results - All 40 PVs could be successfully isolated with a mean of 2.4±0.4 IRE applications per PV. Mean delivered peak voltage and peak current were 2154 ± 59 V and 33.9 ± 1.6 A, respectively. No PV reconnections occurred during the waiting period and adenosine testing. No periprocedural complications were observed. Conclusions - In the 10 patients of this first-in-human study, acute bidirectional electrical PV isolation could be achieved safely by single pulse IRE ablation.

28 March 2025 in EP Europace
Verified
Journal Article
Open access
RTRoland Richard Tilz
Roland Richard Tilz
GCGian Battista Chierchia
Gian Battista Chierchia
MGMelanie A. Gunawardene
Melanie A. Gunawardene
PSPrashanthan Sanders
Prashanthan Sanders
HHHaris Haqqani
Haris Haqqani
DLDhanunjaya Lakkireddy
Dhanunjaya Lakkireddy
Aims: Pulsed field ablation (PFA) is a growing ablation modality for pulmonary vein isolation (PVI) in atrial fibrillation (AF) patients. This study assesses the 6-month safety and effectiveness of a novel balloon-in-basket, mapping-integrated PFA system, with a purpose-built form factor for PVI. Methods and results: The VOLT CE Mark Study is a prospective, multi-center, pre-market study. A total of 150 patients with drug-refractory paroxysmal (PAF) or persistent AF (PersAF) were enrolled between 8 November 2023 and 14 March 2024, of which 146 patients (age 64.1 ± 10.0 years, 63.0% male, 70.5% PAF) underwent PVI with the balloon-in-basket PFA catheter and system featuring integrated electroanatomic mapping with contact-sensing. Study endpoints were the rate of primary serious adverse events within 7 days as well as acute procedural effectiveness and 6-month freedom from recurrence. Acute effectiveness was achieved in 99.1% (573/578) of treated PVs (98.6% of patients, 144/146) with 17.6 ± 5.7 PFA applications/patient. Procedure, fluoroscopy, LA dwell, and transpired ablation times were 100.4 ± 33.0, 17.3 ± 12.1, 39.4 ± 20.6, and 31.4 ± 16.8 min, respectively. There were 4 (2.7%; 4/146) primary serious adverse events. The rate of freedom from documented atrial arrhythmias was 88.2% in PAF patients and 76.7% in PersAF patients (freedom from symptomatic recurrence was documented in 90.2% of PAF patients and 74.4% of PersAF patients) through 6-months post-index procedure. Conclusion: The VOLT CE Mark Study primary results demonstrate the safety and effectiveness of the novel balloon-in-basket PFA system to perform PVI in PAF and PersAF.

24 December 2010 in EP Europace
Verified
Journal Article
Open access
PDF file
IHIrene E. Hof
Irene E. Hof
BVBirgitta K. Velthuis
Birgitta K. Velthuis
SCSevasti-Maria Chaldoupi
Sevasti-Maria Chaldoupi
FWFred H. Wittkampf
Fred H. Wittkampf
VDVincent J. van Driel
Vincent J. van Driel
Peter LohPeter Loh
Peter Loh
Pulmonary vein antrum isolation (PVAI) is an effective treatment for atrial fibrillation (AF); however, its impact on left atrial (LA) size is unknown. This study evaluates the impact of PVAI on LA size, and whether LA size differs between patients with a successful outcome and patients with AF recurrences. Seventy-nine patients (76% male, mean age 56 ± 8 years) with symptomatic, drug refractory AF (70% paroxysmal, 30% persistent/permanent) underwent radiofrequency PVAI. Ablation lesions were created encircling right and left pulmonary venous ostia in pairs. The endpoint was complete isolation of all pulmonary veins. Magnetic resonance imaging was performed before and 4 months after PVAI and LA volume was measured by manually tracing the LA area. Clinical follow-up was at 1, 3, 6, 12, and 24 months. Rhythm status was determined by history, electrocardiogram, and 48 h Holter monitoring. After a mean follow-up of 12 ± 5 months, 62 patients (78%) were free of AF (72% without antiarrhythmic drugs). In the total group, LA volume decreased from 104 ± 27 mL to 91 ± 25 mL, P < 0.001. Patients with a successful outcome showed a decrease in LA volume of 103 ± 27 mL to 89 ± 24 mL, P < 0.001. Among patients with AF recurrences, LA volume decreased from 105 ± 29 mL to 95 ± 27 mL, P = 0.012. No significant difference was seen between the change in LA volume in both subgroups, P = 0.27. Pulmonary vein antrum isolation in patients with AF resulted in a significant decrease of LA size. There was no relation between the decrease in LA size and the recurrence of AF after PVAI.

2 February 2016 in EP Europace
Verified
Journal Article
Closed access
PDF file
CTCas Teunissen
Cas Teunissen
WKWil Kassenberg
Wil Kassenberg
JHJeroen F. van der Heijden
Jeroen F. van der Heijden
RHRutger J. Hassink
Rutger J. Hassink
VDVincent J.H.M. van Driel
Vincent J.H.M. van Driel
Peter LohPeter Loh
Peter Loh
Aims Pulmonary vein antrum isolation (PVAI) is the cornerstone of atrial fibrillation (AF) ablation. There is an ongoing discussion on whether and when to add substrate modification to PVAI. This study evaluates (1) long-term efficacy of PVAI as a primary ablation strategy in all patients independently from AF type and (2) predictors of arrhythmia recurrence. Methods and results A total of 509 consecutive patients (mean age 57 years, 38.9% non-paroxysmal AF) with AF underwent PVAI. In redo procedures, ablation was restricted to re-pulmonary vein (PV) isolation in case of PV reconnection. If the PVs were found to be isolated, substrate modification was performed. In total, 774 procedures were performed. Mean follow-up duration after the first and last ablation was, respectively, 66 ± 23 and 55 ± 25 months. A single PVAI was sufficient in restoring and maintaining long-term sinus rhythm in 41.3% (n = 210) of patients. Multiple procedures (mean 1.5) with re-PV isolation increased long-term success to 58.3% (n = 297). Additional substrate modification (n = 70) increased success to 62.5% (n = 318). After the last ablation, 87.5% of patients experienced success or significant clinical improvement on or off antiarrhythmic drugs. The incidence of left-sided atrial flutter or atrial tachycardia was 5% after PVAI and increased to 32% after additional substrate modification. Independent predictors for arrhythmia recurrence after the last ablation were non-paroxysmal AF, female sex, body mass index, hypertension, and AF duration. Conclusion Five-year freedom of atrial tachyarrhythmia could be achieved by PVAI as primary ablation strategy in 58.3% of patients. Additional substrate modification only moderately increased overall success.

16 April 2025 in JACC: Clinical Electrophysiology
Verified
Journal Article
Closed access
SGSean Gaine
Sean Gaine
TRThomas Rolland
Thomas Rolland
BABabken Asatryan
Babken Asatryan
MLMikael Laredo
Mikael Laredo
JSJames Sampognaro
James Sampognaro
AGAlessio Gasperetti
Alessio Gasperetti

17 February 2020 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RRRob Roudijk
Rob Roudijk
LBLaurens P. Bosman
Laurens P. Bosman
JHJeroen F. van der Heijden
Jeroen F. van der Heijden
JBJacques M. T. de Bakker
Jacques M. T. de Bakker
RHRichard N.W. Hauer
Richard N.W. Hauer
Peter LohPeter Loh
Peter Loh
Fragmented QRS complexes (fQRS) are common in patients with arrhythmogenic cardiomyopathy (ACM). A new method of fQRS quantification may aid early disease detection in pathogenic variant carriers and assessment of prognosis in patients with early stage ACM. Patients with definite ACM (n = 221, 66%), carriers of a pathogenic ACM-associated variant without a definite ACM diagnosis (n = 57, 17%) and control subjects (n = 58, 17%) were included. Quantitative fQRS (Q-fQRS) was defined as the total amount of deflections in the QRS complex in all 12 electrocardiography (ECG) leads. Q-fQRS was scored by a single observer and reproducibility was determined by three independent observers. Q-fQRS count was feasible with acceptable intra- and inter-observer agreement. Q-fQRS count is significantly higher in patients with definite ACM (54 ± 15) and pathogenic variant carriers (55 ± 10) compared to controls (35 ± 5) (p < 0.001). In patients with ACM, Q-fQRS was not associated with sustained ventricular arrhythmia (p = 0.701) at baseline or during follow-up (p = 0.335). Both definite ACM patients and pathogenic variant carriers not fulfilling ACM diagnosis have a higher Q-fQRS than controls. This may indicate that increased Q-fQRS is an early sign of disease penetrance. In concealed and early stages of ACM the role of Q-fQRS for risk stratification is limited.